Dedifferentiated chondrosarcoma: current standards of care.

Dedifferentiated chondrosarcomas are aggressive variants of chondrosarcoma, associated with poor outcomes. Tumor biphasism is the norm. The majority of these tumors are symptomatic at presentation. Radiologically, large soft tissue masses with bony destruction predominate. Treatment protocols of these tumors are not well defined. Surgical resection forms the standard of care for localized disease. (Neo)adjuvant therapies remain controversial as the results from multiple (mainly retrospective) studies remain conflicting. Age at presentation, stage and ability to obtain negative resection margins are important prognostic factors. The overall prognosis is dismal. Newer and novel therapies targeting the complex genetic makeup of these tumors have renewed interest in the adjuvant setting that could hold promise in the near future.

[1]  K. S. Hall,et al.  Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. , 2021, European journal of cancer.

[2]  P. Rutkowski,et al.  Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype , 2021, Cancers.

[3]  Tingting Yang,et al.  Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin , 2020, Journal of bone oncology.

[4]  G. Bianchi,et al.  Lung Metastasectomy Improves Survival in Patients Affected by Grade 2 and 3 Chondrosarcoma , 2020, Oncology Research and Treatment.

[5]  Robin L. Jones,et al.  Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? , 2020, Current Molecular Biology Reports.

[6]  G. Nielsen,et al.  Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution , 2019, Sarcoma.

[7]  R. Grimer,et al.  Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment , 2018, Clinical Sarcoma Research.

[8]  A. Flanagan,et al.  Dedifferentiated Chondrosarcoma Demonstrating Osteosarcomatous Differentiation , 2018, Oncology Research and Treatment.

[9]  Liang Cheng,et al.  Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. , 2017, Human pathology.

[10]  W. Yao,et al.  Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients , 2017, PloS one.

[11]  G. Rosen,et al.  Response to anti-PD1 therapy with nivolumab in metastatic sarcomas , 2016, Clinical Sarcoma Research.

[12]  A. Italiano,et al.  Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype , 2016, Modern Pathology.

[13]  A. Cleton-Jansen,et al.  Targeting survivin as a potential new treatment for chondrosarcoma of bone , 2016, Oncogenesis.

[14]  H. Gelderblom,et al.  Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013 , 2014, Clinical Sarcoma Research.

[15]  A. Sakamoto.  The molecular pathogenesis of dedifferentiated chondrosarcoma , 2014, Indian journal of orthopaedics.

[16]  P. Lin,et al.  Does Ifosfamide Therapy Improve Survival of Patients With Dedifferentiated Chondrosarcoma? , 2014, Clinical orthopaedics and related research.

[17]  A. Flanagan,et al.  Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets. , 2013, The American journal of pathology.

[18]  P. Picci,et al.  Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma , 2012, Genes, chromosomes & cancer.

[19]  O. Merimsky,et al.  Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas , 2012, Cancer Chemotherapy and Pharmacology.

[20]  A. Cleton-Jansen,et al.  Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F. Bertucci,et al.  Advanced chondrosarcomas: role of chemotherapy and survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. McPherson,et al.  Antibody targeting of TGF-β in cancer patients. , 2011, Current pharmaceutical biotechnology.

[23]  A. Cleton-Jansen,et al.  Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo , 2011, Clinical Sarcoma Research.

[24]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[25]  D. Biau,et al.  Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. , 2007, European journal of cancer.

[26]  A. Đorđević,et al.  Dedifferentiated chondrosarcoma: our clinico-pathological experience and dilemmas in 25 cases , 2007, Journal of Cancer Research and Clinical Oncology.

[27]  F. Bertoni,et al.  Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. , 2007, The Journal of bone and joint surgery. American volume.

[28]  F. Bertoni,et al.  Dedifferentiated central chondrosarcoma , 2006, Cancer.

[29]  F. Sim,et al.  Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. , 2004, The Journal of bone and joint surgery. American volume.

[30]  L. White,et al.  Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: a retrospective review of 174 de novo cases. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[31]  F. Sim,et al.  Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. , 1986, The Journal of bone and joint surgery. American volume.

[32]  S. Schleicher,et al.  Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance , 2018, International journal of molecular sciences.

[33]  Kyung-Ja Cho,et al.  Chondrosarcoma: With Updates on Molecular Genetics , 2011, Sarcoma.

[34]  M. Nooij,et al.  Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. , 2005, European journal of cancer.